Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Trial Profile

Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Beraprost (Primary) ; Aspirin
  • Indications Atherosclerosis; Coronary arteriosclerosis; Embolism and thrombosis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 May 2016 Status changed from recruiting to discontinued.
    • 21 May 2012 Planned end date (31 Dec 2013) added as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top